|
| Publications |
PublicationsMy publications | Book Chapters | Patents | Publications about my researchMy publications36. C. Vrijman, M.W. Kroon, J. Limpens , M.M. Leeflang, R.M. Luiten, J.P. van der Veen, A. Wolkerstorfer, Ph.I. Spuls. The prevalence of thyroid disease in vitiligo patients: a systematic review.Br J Dermatol. 2012, in press 35. P. Weder, T. N.M. Schumacher, H. Spits, R.M. Luiten. Testing for HLA/peptide tetramer-binding to the T cell receptor complex on human T lymphocytes. Results in Immunology 2012, May 17, 88-96. 34. Y. Jin, S.A. Birlea, P.R. Fain, T.M. Ferrara, S. Ben, S.L. Riccardi, J.B. Cole, K. Gowan, P.J. Holland, D.C. Bennett, R.M. Luiten, A. Wolkerstorfer, J.P. van der Veen, A. Hartmann, S. Eichner, G. Schuler, N. van Geel, J. Lambert, E.H. Kemp, D.J. Gawkrodger, A.P. Weetman, A. Taïeb, T. Jouary, K. Ezzedine, M.R. Wallace, W.T. McCormack, M. Picardo, G. Leone, A. Overbeck, N.B. Silverberg, R.A. Spritz. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet. 2012 May 6, in press 33. K. Szegedi, A.E. Kremer, S. Kezic, M.B.M. Teunissen, J.D. Bos, R.M. Luiten, P.C. Res, M.A. Middelkamp-Hup. Increased frequencies of IL-31 producing T cells are found in Chronic Atopic Dermatitis skin. Exp. Derm. 2012, in press 32. V.Stroobant, N. Demotte, R.M. Luiten, R.M. Leonhardt, P. Cresswell, A.Bonehill, A. Michaux, W. Ma, A. Mulder, B.J. Van den Eynde, P. van der Bruggen, N. Vigneron. Exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be restored by acid treatment or fixation of target cells. Eur. J. Immunol. 2012, in press. 31. M.W. Kroon, E. H. Kemp, B.S. Wind, G. Krebbers, J.D. Bos, D.J. Gawkrodger, A. Wolkerstorfer, J.P.W. van der Veen, R.M. Luiten. Melanocyte antigen- specific antibodies can not be used as markers for recent disease activity. J. Eur. Acad. Dermatol. Venereol. 2012, in press. 30. M.W. Kroon, I.C. Joore, B.S. Wind, M.A. Leloup, A. Wolkerstorfer, R.M. Luiten, J.D. Bos, R.B. Geskus, J.P.W. van der Veen. Low yield of routine screening for thyroid dysfunction in asymptomatic vitiligo patients. Br. J. Dermatol. 2012, 166(3):532-538. 29. R. Speeckaert, N.van Geel, R.M. Luiten, M. Van Gele, M. Speeckaert, J. Lambert, K. Vermaelen, E.P.M. Tjin, L. Brochez. Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma. Anticancer Res, 2011, 31(11):3697-703. 28. N. van Geel, R. Speeckaert, I. Mollet, S. De Schepper, J. De Wolf, E.P. Tjin, R.M. Luiten, J. Lambert, L. Brochez. In vivo vitiligo induction and therapy model : double blind, randomized clinical trial. Pigment Cell Melanoma Res. 2012, 25(1):57-65. 27. E.P. Tjin, D Konijnenberg, G. Krebbers, H. Mallo, J.W. Drijfhout, K.L. Franken, C.M. van der Horst, J.D. Bos, O.E. Nieweg, B.B. Kroon, J.B. Haanen, C.J. Melief, F.A. Vyth-Dreese, R.M. Luiten. T cell immune function in tumor, skin and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin. Cancer Res. 2011, 17(17):5736-5747. 26. J.G. van den Boorn JG, C.J. Melief, R.M. Luiten. Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity. Pigment Cell Melanoma Res. 2011, 24(4):673-679. 25. J.G. van den Boorn, D.I. Picavet, P.F. van Swieten, H.A. van Veen, D. Konijnenberg, P.A. van Veelen, T. van Capel, E.C. de Jong, E.A. Reits, J.W. Drijfhout, J.D. Bos, C.J. Melief and R.M. Luiten. Skin-depigmenting agent monobenzone induces potent T cell autoimmunity towards pigmented cells by tyrosinase haptenation and melanosome autophagy. J. Invest Dermatol. 2011, 131(6):1240-51. 2011, in press. Featured on the issue cover, and as Editorial, J. Invest Dermatol. 2011, Jun;131(6):1185-7. 24. L. Nieuweboer-Krobotova en R.M. Luiten. Over immuungemedieerde dermatosen: Vitiligo: pathogenese, diagnose, behandeling en de relatie tot melanoom. Ondermeer 2010, 25: 3-12. 23. R.M. Luiten. Chemo-immunotherapie van kanker. Folia Pharmaceutica 2010, 98(1): 11-13. 22. J.G. van den Boorn, D. Konijnenberg, E.P.M. Tjin, D.I. Picavet, N.J. Meeuwenoord, D.V. Filippov, J.P.W. van der Veen, J.D. Bos, C.J.M. Melief, R.M. Luiten. Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG PloS ONE 2010, published 13 May 2010, [download article] 21. N.A. van Geel, I.G. Mollet, S. De Schepper, E.P.M. Tjin, K. Vermaelen, R.A. Clark, T.S. Kupper, R.M. Luiten, J. Lambert. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res. 2010; 23(3):375-384. 20. J.G. van den Boorn, D. Konijnenberg, T.A.M. Dellemijn, J.P. W. van der Veen, J.D. Bos, C.J.M. Melief, F.A. Vyth-Dreese and R.M. Luiten. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J. Invest. Dermatol, 2009, 129: 2220–2232. 19. R.M. Luiten. Vitiligo bij melanoom: verlichting van een woekering, Ned. Tijschr. Dermat. Venereol. 2009, 19(3):114-115. 18. K.U. Schallreuter, P. Bahadoran, M. Picardo, A. Slominski, Y.E. Elassiuty, E.H. Kemp, C. Giachino, J.B. Liu, R.M. Luiten, T. Lambe, I.C. Le Poole, I. Dammak, H. Onay, M.A. Zmijewski, M.L. Dell'Anna, M.P. Zeegers, R.J. Cornall, R. Paus, J.P. Ortonne and W. Westerhof. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Controversies in Experimental Dermatology, Experimental Dermatology 2008, 17(2): 139-140. 17. RM Luiten. Vitiligo bij melanoom: een gunstig teken. Nederlands Tijdschrift voor Oncologie 2006, jaargang 3, nr 6:224-230 [in pdf]. 16. E.A. Reits, J.W. Hodge, C.A. Herberts, M. Chakraborty, E.K. Wansley, K. Camphausen, J. Schlom, R.M. Luiten, A de Ru, TA Groothuis, A Griekspoor, E Mesman, F Verreck, H Spits, P van Veelen, JJ Neefjes. Radiation modulates the peptide repertoire of MHC class I molecules and induces successful anti- tumor immunotherapy. J Exp Med, 2006; 203(5):1259-71. 15. J.G. van den Boorn, I.C. LePoole, R.M. Luiten. T cell avidity and tuning: the flexible connection between tolerance and autoimmunity. International Reviews of Immunology 2006;25(3-4):235-58. 14. K. Oyarbide-Valencia, J.G. van den Boorn, C. Denman, J. Carlson, C. Hernandez, M.I. Nishimura, P.K. Das, R.M. Luiten and I.C. Le Poole. Therapeutic implications of autoimmune vitiligo T cells. Autoimmunity Reviews 2006; 5(7):486-92. 13. RM Luiten, E.W.M. Kueter, W. Mooi, M.P.W. Gallee, E.M. Rankin, W.R. Gerritsen, S.M. Clift, W.J. Nooijen, P.Weder, W.F. van de Kasteele, J. Sein, P.C.M. van den Berk, O.E. Nieweg, A.M. Berns, H. Sptis and G.C. de Gast. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. Journal of Clinical Oncology. 2005; 23(35), [pdf] Featured as editorial by William E. Carson [in pdf] 12. N.C.V. Verra, A. Jorritsma, K. Weijer, J.J. Ruizendaal, A. Voordouw, P. Weder, E. Hooijberg, T.N.M. Schumacher, J.B.A.G. Haanen, H. Spits and R.M. Luiten. hTERT-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Research. 2004, 64:2153-2161. [pdf]
10. RM Luiten, J Pène, H Yssel and H Spits. Ectopic hTERT expression extends the life span of human CD4+ helper and regulatory T cell clones and confers resistance to oxidative stress-induced apoptosis Blood. 2003; 101(11): 4512-9. [pdf] 9. Luiten RM, Demotte N, Tine J, van der Bruggen P. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Tissue Antigens. 2000 Jul;56(1):77-81. [PubMed] 8. Luiten R, van der Bruggen P.A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. Tissue Antigens. 2000; 55(2):149-52. [PubMed] 7. Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol. 1999; 163(5):2928-36. [pdf] 6. Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999; 189(5):767-78. [pdf] 5. Luiten RM, Coney LR, Fleuren GJ, Warnaar SO, Litvinov SV. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br J Cancer. 1996; 74(5):735-44. [PubMed] 4. Luiten RM, Fleuren GJ, Warnaar SO, Litvinov SV. Target-specific activation of mast cells by immunoglobulin E reactive with a renal cell carcinoma associated antigen. Lab Invest. 1996; 74(2):467-75. [PubMed] 3. Luiten RM, Warnaar SO, Sanborn D, Lamers CH, Bolhuis RL, Litvinov SV, Zurawski VR Jr, Coney LR. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients. J Immunother. 1997; 20(6):496-504. [PubMed] 2. Luiten RM, Warnaar SO, Schuurman J, Pasmans SG, Latour S, Daeron M, Fleuren GJ, Litvinov SV. Chimeric immunoglobulin E reactive with tumor-associated antigen activates human Fc epsilon RI bearing cells. Hum Antibodies. 1997;8(4):169-80. [PubMed] 1. de Koster HS, Kenter MJ, D'Amaro J, Luiten RM, Schroeijers WE, Giphart MJ, Termijtelen A. Positive correlation between oligonucleotide typing and T-cell recognition of HLA-DP molecules. Immunogenetics. 1991;34(1):12-22. [PubMed] Book ChaptersJan D. Bos and Rosalie M. Luiten Caroline Le Poole and Rosalie M. Luiten Patents4. W. Westerhof, R.M. Luiten, C.J.M. Melief. Sensitization of the immune systems against haptenized melanoma antigens. Patent nr. US 11/996,753 - EU 05769178.4 - CA 2,615,710 – AU 2005334836. Publication date: 2008-08-21 3. Chaux, R.M. Luiten, N. Demotte, M.T. Duffour, C. Lurquin, C. Traversari, V. Stroobant, G.R. Cornelis, T. Boon-Falleur, P. van der Bruggen, E Schultz and G. Warnier. Tumor antigens and CTL clones isolated by a novel procedure 2. R.M. Luiten, T. Boon-Falleur, P. van der Bruggen, V. Stroobant, N. Demotte and E. Schultz. MAGE antigenic peptides, which bind HLA-B35 and B44 1. P. Chaux, T. Boon-Falleur, R.M. Luiten, C. Heirman, V. Stroobant, J. Corthals, K. Thielemans, P. van der Bruggen. MAGE-3 peptides presented by HLA Class II molecules. Publications about my research9. Breaking immunological tolerance to melanocyte differentiation antigens by hypopigmenting agents: a new means for melanoma immunotherapy? Becker JC, Schrama D. Editorial, J Invest Dermatol. 2011 Jun;131(6):1185-7. 8. Crème als immuuntherapie voor melanoom. Mednet 06, 2011: 38 7. Melanoombehandeling met crème (MI therapie). Melanoomnieuws Stichting Melanoom 2011; 13(2): 8-9. 6. Bleke huid tegen kanker. Melanoom: ziekte met ziekte bestrijden. AMC magazine May 2011; 5: 4-5. (Magazine of the Academic Medical Center, University of Amsterdam, The Netherlands). 5: A press release about the disseratation of my phd-student Jasper van den Boorn drew a lot of media attention. It was published in De Telegraaf (the biggest newspaper in the Netherlands), but also on a lot of newswebsites, like Nu.nl, Metro, Medicalfacts.nl, Gezondheidsnet.nl, Artsennet.nl, Zorg.nieuwslog, Folia.nl, Amsterdam Biomed and Drimble weblog. It also led to an interview on BNR Newsradio. 4. E. Gerritsma "De werkplek", Status, May 2007 (interview with R.M. Luiten) 3. J. Ekkelboom "Therapie met witte vlekken. Een kleurloos wapen tegen huidkanker", AMC magazine 3, 2006; 20-21. 2. W. Carson. "Getting melanoma cells to stimulate with frequency" Editorial, J. Clin. Oncol. 2005; 23(35): 8929-8931. [in pdf] 1. I. van Elsakker. "Witte vlekken tegen huidkanker", AMC magazine 2005; 5:30. In addition, more than 5 press releases were published by the University of Leiden, Amsterdam and The Netherlands Organization of Scientific Research to announce the candidate as Laureate of the NWO-VIDI personal fellowship. Other publications8. "Meer succes met therapie voor vitiligo", Newsletter January 2006 of the LVVP (not online anymore), The Dutch Society of Vitiligo Patients 7. "Communicating European Research: the importance of explaining science to the public", Report of the EC conference CER2005 (Brussels, November 2005 ), MCFA website 6. "The Europe of Knowledge: a blueprint for competitive research in Europe", Report of EC conference Europe of Knowlegde 2020 (Liège, April 2004), MCFA website. 5. "Europe's hope: the strategy of togetherness", Report of the Thursday meeting of the EESC (Brussels, January 2006), MCFA website 4. MCFA Welcome Document for the Belgian MCFA Group, MCFA website 3. Minutes of the MCFA First National Co-ordinators meeting (London, June 1999). 2. Meeting of the Dutch national group. 1. Minutes of the first Belgian group meeting. Rosalie Luiten has held more than 20 oral and poster presentations on the subject of cancer research, immunotherapy and gene therapy at international conferences, such as the Keystone symposia, Cancer Research Institute symposia and the European Society of Gene Therapy. She published the abstracts of these presentations in conference proceedings.
Delen | . Ontwerp en realisatie: Nico van Dijk Media
|
11. A Röth, H Yssel, J Pène, EA Chavez, M Schertzer, PM Lansdorp, H Spits and RM Luiten. Telomerase levels control the lifespan of human T lymphocytes. Blood, 2003; 102(3): 849-57. [
Top